Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

The US Food and Drug Administration (FDA) on Thursday released an alert and summary of findings from two halted Merck clinical trials evaluating the use of Keytruda (pembrolizumab) combined with other ...

Results from the key secondary endpoint of OS showed a 50% reduction in the risk of death for neoadjuvant and adjuvant PADCEV plus KEYTRUDA as compared to surgery alone (HR of 0.50; 95% CI, 0.33-0.74; ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival ...

Earlier this week, the European Commission approved Merck’s ENFLONSIA (clesrovimab), a long-acting monoclonal antibody to ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.